Multivariate analysis in the pharmaceutical industry: enabling process understanding and improvement in the PAT and QbD era

被引:74
作者
Ferreira, Ana P. [1 ]
Tobyn, Mike [1 ]
机构
[1] Bristol Myers Squibb Co, Dept Drug Prod Sci & Technol, Wirral CH46 1QW, Merseyside, England
关键词
Partial least squares regression; principal component analysis; process analytical technology; quality by design; NEAR-INFRARED SPECTROSCOPY; CHEMOMETRICS; REGRESSION; DESIGN; TOOLS; QUALITY; SIZE;
D O I
10.3109/10837450.2014.898656
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the pharmaceutical industry, chemometrics is rapidly establishing itself as a tool that can be used at every step of product development and beyond: from early development to commercialization. This set of multivariate analysis methods allows the extraction of information contained in large, complex data sets thus contributing to increase product and process understanding which is at the core of the Food and Drug Administration's Process Analytical Tools (PAT) Guidance for Industry and the International Conference on Harmonisation's Pharmaceutical Development guideline (Q8). This review is aimed at providing pharmaceutical industry professionals an introduction to multivariate analysis and how it is being adopted and implemented by companies in the transition from "quality-by-testing'' to "quality-by-design''. It starts with an introduction to multivariate analysis and the two methods most commonly used: principal component analysis and partial least squares regression, their advantages, common pitfalls and requirements for their effective use. That is followed with an overview of the diverse areas of application of multivariate analysis in the pharmaceutical industry: from the development of real-time analytical methods to definition of the design space and control strategy, from formulation optimization during development to the application of quality-by-design principles to improve manufacture of existing commercial products.
引用
收藏
页码:513 / 527
页数:15
相关论文
共 67 条
[1]  
[Anonymous], 2009, Q8 R2 PHARM DEV INT
[2]  
[Anonymous], 1935, Bull. Am. Iris Soc.
[3]  
Armstrong NA., 2006, PHARM EXPT DESIGN IN
[4]   Bad results from good data [J].
Badertscher, Martin ;
Pretsch, Erno .
TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2006, 25 (11) :1131-1138
[5]  
Bijnens L, 2009, COMPREHENSIVE CHEMOMETRICS: CHEMICAL AND BIOCHEMICAL DATA ANALYSIS, VOLS 1-4, pC197
[6]  
Brereton R.G., 2003, DATA ANAL LAB CHEM P
[7]   Process analytical tools for monitoring, understanding, and control of pharmaceutical fluidized bed granulation: A review [J].
Burggraeve, Anneleen ;
Monteyne, Tinne ;
Vervaet, Chris ;
Remon, Jean Paul ;
De Beer, Thomas .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2013, 83 (01) :2-15
[8]   Estimation of ADME properties in drug discovery:: Predicting Caco-2 cell permeability using atom-based stochastic and non-stochastic linear indices [J].
Castillo-Garit, Juan A. ;
Marrero-Ponce, Yovani ;
Torrens, Francisco ;
Garcia-Domenech, Ramon .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (05) :1946-1976
[9]   Chemometrics-Based Process Analytical Technology (PAT) Tools: Applications and Adaptation in Pharmaceutical and Biopharmaceutical Industries [J].
Challa, Shruthi ;
Potumarthi, Ravichandra .
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2013, 169 (01) :66-76
[10]   Trends in process analytical technology [J].
Chew, Wee ;
Sharratt, Paul .
ANALYTICAL METHODS, 2010, 2 (10) :1412-1438